Pharmaceutical Executive-11-01-2018

November 23, 2018

As CAR-T therapy eyes new territory-solid tumors-and expands into autoimmune disease, other frontiers in drug development are beginning to open up. They highlight the raw promise of science, with cannabis-based agents targeting CNS and rare genetic disorders, as well as the larger responsibility to public health, including advancing non-opioid alternatives, addressing antibiotic, and untangling the path to market for biosimilars.

November 14, 2018

Regulators, prosecutors shifting enforcement focus from off-label promotion to messages that raise safety issues, mislead.

November 14, 2018

The increase in new drug approvals and candidates in development are good signs for pharma and biotech, but both sectors face continued pricing, cost, and healthcare policy-related challenges ahead.

November 13, 2018

Amid a still-difficult environment for enforcing cannabis-related patents, this article explores some of the types of patent protection available for cannabis-based therapies and inventions.

November 12, 2018

As this year's Pipeline Report illustrates, there remains an imbalance between funding and incentivizing new drug discovery in some therapeutic areas and rewarding the risk-based nature of these innovations. Imagine if we could solve this conundrum in science?

November 11, 2018

Pharm Exec examines the booming life sciences scene in southeast Virginia and Raleigh-Durham and Winston-Salem, North Carolina-and the region’s advantages in location, talent, and funding compared to the more glamour spots up north.

November 10, 2018

Analysts from Informa Intelligence take a deeper dive into these three pivotal areas of R&D today-the crisis points and progress.

November 06, 2018

Parliament throws wrench in Commission’s plan to regulate HTA.

November 06, 2018

Data shows cultural gaps and highlights a C-level fix.

November 01, 2018

Click the title above to open the Pharmaceutical November 2018 issue in an interactive PDF format.

November 01, 2018

Despite a recent whirlwind of changes and policy reshuffling in Algeria’s life science space, the nation’s marketplace remains a high priority for multinationals investing in the Middle East and North Africa (MENA).